ERBB2 and neoplasm: Among patients with sHR-positive/HER2-negative tumours and a low uPA/PAI-1 status, 97.1% remained recurrence free, compared to 91.5% with a high uPA/PAI-1 status (HR 2.74, 95% CI 1.238–6.071, p = 0.013) (Fig. 3, Supplementary Fig. S1A).